Ixekizumab

Taltz® Ixekizumab

Eli Lilly

Humanised monoclonal IgG4 antibody that binds to and blocks IL-17A.

Moderate to severe plaque psoriasis (from 6 years of age and 25 kg),
Psoriatic arthritis in adults.

Yes

Treatment of adult patients with severe plaque psoriasis (as defined by the USZ and the Swiss S1 Guideline: PASI > 10 or BSA > 10 and/or DLQI > 10), in whom UVB and PUVA or one of the following three systemic therapies (cyclosporine, methotrexate, acitretin) have failed to produce a therapeutic response. Active psoriatic arthritis that has responded inadequately to treatment for plaque psoriasis with one or more DMARDs or which has not been tolerated by the patient.

Pre-filled pen

Differential blood count, liver function tests, creatinine, urinalysis, pregnancy test, CRP, screening for HBV, HCV, HIV and TB (optional: including chest X-ray).

Not necessary, only clinically.

Every 6 months, clinical only.

s.c

The recommended dose is 160 mg as a subcutaneous injection (two 80 mg injections) in week 0, followed by 80 mg (one injection) in weeks 2, 4, 6, 8, 10 and 12, and thereafter 80 mg (one injection) every 4 weeks.

For patients weighing <100 kg, an alternative dosing regimen of 160 mg in week 0 and 80 mg every 4 weeks from week 2 onwards may be considered. For the recommended dose for subcutaneous injection in paediatric patients aged 6 years and over with a body weight of at least 25 kg, see the summary of product characteristics.

If no therapeutic success has been achieved after 20 weeks, the treatment should be discontinued.

77.5–84.2 % after 12 weeks on 80 mg Taltz administered every 4 weeks

87.3–89.7 % after 12 weeks on 80 mg Taltz administered every 2 weeks

59.7–65.3% after 12 weeks of 80 mg Taltz administered every 4 weeks

68.1–70.9% after 12 weeks of 80 mg Taltz administered every 2 weeks

> 100 kg: 14,401 (19,205)

< 100 kg: 14,401 (16,800)

87–95 per cent achieve this again upon retreatment after 24 weeks

PASI 75

PASI (use PrecisePASI for greater accuracy when PASI < 10), BSA and DLQI at 12 and 24 weeks.

Detected in 1.7 % of cases.

Absolute contraindications: Active tuberculosis or acute, severe infections, live vaccines, active chronic hepatitis B, pregnancy and breastfeeding.

Relative contraindications: Crohn’s disease (close monitoring), malignant diseases (except BCC and lymphoproliferative disorders).

Candida infections (0.4 %), including oral and oesophageal involvement, local reactions at the injection site, upper respiratory tract infections, tinea infection, nausea, diarrhoea, elevated liver enzymes, oropharyngeal pain, thrombocytopenia.

Insufficient data

Insufficient data

Insufficient data

The dosage of medicines that interact with CYP450 3A4, 1A2 or 2C9 should be reassessed.

Requires treatment with isoniazid and vitamin B6 for 9 months; treatment with a biologic may be started after 1 month

Insufficient data